Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Operating Income Loss of $4.17 billion for the year ending 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +1,891.9% in Operating Income Loss from 2024 to 2025.
- This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), VERTEX PHARMACEUTICALS INC / MA's Operating Income Loss has grown by 1,001.9%.
- Historical annual values: Fiscal year 2025: $4.17 billion | Fiscal year 2024: -$232.90 million | Fiscal year 2023: $3.83 billion | Fiscal year 2022: $4.31 billion | Fiscal year 2021: $2.78 billion | Fiscal year 2020: $2.86 billion | Fiscal year 2019: $1.20 billion | Fiscal year 2018: $635.15 million | Fiscal year 2017: $123.24 million | Fiscal year 2016: $9.94 million | Fiscal year 2015: -$466.88 million | Fiscal year 2014: -$692.41 million | Fiscal year 2013: -$610.01 million | Fiscal year 2012: $46.73 million | Fiscal year 2011: $113.82 million | Fiscal year 2010: -$696.08 million | Fiscal year 2009: -$614.01 million | Fiscal year 2008: -$462.71 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: